DDN June 2017

‘Most drug-related deaths are of people not in treatment’ By the end of this week the next government will have been chosen – and who knows,...

Slow on the draw

Why are smokers reluctant to exchange the risks of cigarettes for the health benefits of e-cigs, asks Neil McKeganey. E-cigarettes have been characterised by Public...

On a mission to cure hep C

Curing hepatitis C has become a reality and makes sense for the public purse as well as public health. So let’s get on with...

Vote of confidence

As Phoenix Futures launches its new strategy, with the strapline ‘The charity that is confident about recovery’, DDN hears about the ideas behind it...

A different pain

James Elander shares his new research on painkiller addiction and how to spot the warning signs. Addiction to prescribed pain relief is a serious and...

The emperor’s new clothes

Pockets of good practice throughout the country should not mask the fact that the ‘recovery agenda’ is failing, says Howard King. Since the end of...

On borrowed time

The delayed drug strategy – and lack of plan for an alcohol strategy – is pulling the lifeline from a sector in crisis, hears...

DDN May 2017

‘Who can offer the political leadership the sector needs?' Hogwash and purdah – it’s election season again and where is the long-awaited drug strategy? The...

Stuck in the system

New treatment for hepatitis C has opened up massive opportunity for all-round health gains that we are just not taking, hears DDN. We need to...

Under pressure

The celebrity craze for stress pills is even reaching schoolchildren – should we be concerned? Kevin Flemen looks at the risks and availability of...